Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.87
DRTX's Cash to Debt is ranked higher than
60% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. DRTX: 0.87 )
DRTX' s 10-Year Cash to Debt Range
Min: 0.87   Max: No Debt
Current: 0.87

Z-Score: 6.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -182.82
DRTX's ROE (%) is ranked higher than
54% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -25.77 vs. DRTX: -182.82 )
DRTX' s 10-Year ROE (%) Range
Min: -1188.24   Max: -150.73
Current: -182.82

-1188.24
-150.73
ROA (%) -67.12
DRTX's ROA (%) is ranked higher than
58% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. DRTX: -67.12 )
DRTX' s 10-Year ROA (%) Range
Min: -196.48   Max: -66.57
Current: -67.12

-196.48
-66.57
ROC (Joel Greenblatt) (%) -6864.28
DRTX's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. DRTX: -6864.28 )
DRTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -12758.41   Max: -6067.31
Current: -6864.28

-12758.41
-6067.31
» DRTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

DRTX Guru Trades in

DRTX Guru Trades in

Q1 2014

DRTX Guru Trades in Q1 2014

Jim Simons 60,300 sh (New)
» More
Q2 2014

DRTX Guru Trades in Q2 2014

Jim Simons 66,200 sh (+9.78%)
» More
» Details

Insider Trades

Latest Guru Trades with DRTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 239.90
DRTX's P/B is ranked lower than
61% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. DRTX: 239.90 )
DRTX' s 10-Year P/B Range
Min: 0   Max: 240.9
Current: 239.9

0
240.9
EV-to-EBIT -11.18
DRTX's EV-to-EBIT is ranked higher than
58% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. DRTX: -11.18 )
DRTX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -11.18

Current Ratio 3.76
DRTX's Current Ratio is ranked higher than
73% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. DRTX: 3.76 )
DRTX' s 10-Year Current Ratio Range
Min: 0.65   Max: 5.88
Current: 3.76

0.65
5.88
Quick Ratio 3.76
DRTX's Quick Ratio is ranked higher than
74% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. DRTX: 3.76 )
DRTX' s 10-Year Quick Ratio Range
Min: 0.65   Max: 5.88
Current: 3.76

0.65
5.88

Valuation & Return

vs
industry
vs
history

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:DTA.Germany
Durata Therapeutics Inc is a clinical development stage biopharmaceutical company. The Company develops and commercializes novel therapeutics for patients with infectious diseases and acute illnesses.
» More Articles for DRTX

Headlines

Articles On GuruFocus.com
Three Stocks With Massive Insider Buying Sep 03 2014 
Ttreatment for skin Aug 05 2012 

More From Other Websites
Nasdaq stocks posting largest percentage increases Oct 22 2014
Durata Therapeutics downgraded by ROTH Capital Oct 15 2014
INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Durata... Oct 14 2014
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Durata Therapeutics, Inc. in... Oct 11 2014
DURATA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Durata Therapeutics... Oct 10 2014
DURATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of... Oct 10 2014
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Durata... Oct 10 2014
Durata Therapeutics Presents New Data for DALVANCE(TM) at IDWeek 2014(TM) Oct 10 2014
Harwood Feffer LLP Announces Investigation of Durata Therapeutics, Inc. Oct 09 2014
DURATA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Oct 09 2014
Lifshitz & Miller Law Firm Announces Investigation of Altair Nanotechnologies, Inc., CareFusion,... Oct 07 2014
INVESTOR ALERT: The Law Offices of Vincent Wong Investigates the Board of Directors of Durata... Oct 07 2014
DURATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of... Oct 07 2014
Ryan & Maniskas, LLP Announces Investigation of Durata Therapeutics, Inc. Oct 07 2014
INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Durata... Oct 07 2014
DURATA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Durata Therapeutics... Oct 06 2014
Actavis expands antibiotics Oct 06 2014
INVESTOR ALERT: The Law Offices of Vincent Wong Investigates the Board of Directors of Durata... Oct 06 2014
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Durata... Oct 06 2014
DURATA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Oct 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK